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INTRODUCTION
Asthma-chronic obstructive pulmonary disease (COPD) over-
lap syndrome (ACOS) has been defined as a condition charac-
terized by several features of asthma and COPD by the Global 
Initiative for Asthma (GINA) and Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) committees in 2014. COPD 
is characterized by irreversible airflow limitation associated with 
aging and smoking, whereas asthma is characterized by revers-
ible airflow limitation associated with atopic features.1-3 Asthma 
is a completely different disease from COPD in its pathophysi-
ology;4 Therefore, many studies have reported that ACOS is a 
distinct phenotype of COPD.5-7 However, there has been no con-
sensus regarding how different ACOS is from COPD in its clini-
cal characteristics and prognosis. Many studies have reported 
that patients with ACOS have more severe respiratory symptoms, 
a more greatly impaired quality of life, more frequent exacerba-
tions, and more comorbidities compared with patients with 
COPD.8-10 However, some studies have reported no significant 
difference between them.5 Moreover, other recent studies re-
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ported that patients with ACOS had better prognoses, including 
mortality and lung function.11,12
The aim of this study was to determine whether the clinical 
characteristics and prognoses of patients with asthma-COPD 
overlap (ACO) which indicates a generous term of ACOS defined 
by Barnes9 and the 2017 GINA guideline13 differ from those of 
patients with pure COPD. 
MATERIALS AND METHODS
Data collection
We analyzed data from a Korean COPD Subtype Study (KO-
COSS) cohort collected from 45 study centers throughout Ko-
rea.14 Recruitment, enrollment, and measurement occurred be-
tween December 2011 and October 2016. Enrollment criteria 
for the KOCOSS cohort were Korean adults ≥40 years old with 
a post-bronchodilator (BD) forced expiratory volume in 1 sec-
ond (FEV1)/forced vital capacity (FVC) value <0.7 at any clini-
cal visit. Exclusion criteria were subjects who (1) could not per-
form the pulmonary function test, (2) used systemic steroids 
because of other underlying diseases, and (3) could not com-
municate with clinicians. Smoking history and status, respira-
tory symptoms including coughing and sputum, and comor-
bidities were assessed at the first visit. All data were collected by 
trained nurses, and patients were followed up at 6-month regu-
lar intervals. A pulmonary function test was performed for all 
subjects and blood sampling was performed at the first visit. The 
total immunoglobulin E (IgE) level and absolute eosinophil count 
were analyzed from the obtained blood samples.
Patient selection by COPD and ACO definitions
Among the 1,675 patients enrolled in the KOCOSS cohort, 1,504 
were diagnosed with COPD based on a pulmonary function 
test with a post-BD FEV1/FVC <0.7 at the first visit. The occur-
rence of ACO was defined as a positive response to a BD (an in-
crease in FEV1 of 12% and 200 mL). Then, 1,281 patients were 
diagnosed with “pure” COPD and 223 patients were diagnosed 
with ACO (Fig. 1).
Among them, 834 were followed up for more than 2 years and 
analyzed to define exacerbation rate for 2 years. Additionally 
189 patients were followed up with pulmonary function tests at 
1-year intervals for more than 3 years and analyzed to define 
change in lung function for 3 years.
COPD assessment test (CAT) and St. George Respiratory 
Questionnaire scores
The CAT score and St. George Respiratory Questionnaire for 
COPD patients (SGRQ-C) score were used to assess health sta-
tus in patients with COPD. The CAT consists of 8 items and in-
cludes questions on symptoms, energy, sleep, and activity. A 
higher score indicates more severe symptoms.15 The SGRQ-C 
includes 40 items and contains 3 parts scoring symptoms, ac-
tivities, and impacts on daily life. Total and component scores 
were calculated according to algorithms provided in the SGRQ-
C instruction manual. A higher score means a poorer quality of 
life.16
Exacerbation definition
Exacerbation was defined as the worsening of any respiratory 
symptom, such as increased sputum volume, purulence, or in-
creased dyspnea, which required treatment with systemic cor-
ticosteroids, antibiotics, or both. Exacerbation history in the pre-
vious 12 months was assessed at the first visit, the 1-year follow-
up visit, and the 2-year follow-up visit.
Statistical analysis
For continuous variables, descriptive statistics are reported as 
means with standard deviations (SDs), and for categorical vari-
ables as the number of patients per category and the frequency 
of responses. Comparisons of continuous variables were made 
using the 2-sample t test; the χ2 test or Fisher’s exact test were 
used for comparisons of categorical variables. Comparisons of 
FEV1 changes over time were assessed with a repeated analysis 
of variance (ANOVA). Differences were considered statistically 
significant at P<0.05.
Ethics statement
The protocol was approved by the Institutional Review Board 
at each center. All patients provided written informed consent 
for participation in the study. 
RESULTS
Comparisons of demographics and clinical characteristics 
between the pure COPD and ACO group
Among 1,504 patients with COPD, 223 (14.8%) were diagnosed 
Fig. 1. Study flow. KOCOSS, Korean Chronic Obstructive Pulmonary Disease 
Subtype Study; COPD, chronic obstructive pulmonary disease; ACO, asthma-
chronic obstructive pulmonary disease overlap.
1,675 patients
in KOCCOS
171 patients are 
excluded
1,504 patients were 
diagnosed as COPD
1,281 patients were 
diagnosed as COPD
223 patients were 
diagnosed as ACO
Comparisons of ACO and Pure COPD
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with ACO after presenting a bronchodilator response (BDR). 
The pure COPD group had more women (9.5%) than the ACO 
group (4.5%; P=0.015). The ACO group had more current smok-
ers (32.9%) than the pure COPD group (25.3%; P=0.026). Al-
though the prevalences of coughing and sputum were not dif-
ferent between the 2 groups, patients with ACO reported a bet-
ter quality of life (SGRQ-C score=31.0±18.0 [mean±standard 
deviation]) than those with pure COPD (35.3±19.1) (P=0.002). 
There was no significant difference in lung function or comor-
bidities between the 2 groups (Table 1). Although the data are 
not shown, the prevalence of a treatment-naïve status (7.7% and 
11.6%), mean duration of treatment for COPD (5.3±5.3 and 
4.9±4.6 years), or prevalence of a history of inhaled corticoste-
roids (ICS) use (83.1% and 82.5%) was not significantly different 
between the COPD and ACO groups.
Comparisons of prognoses between the COPD and ACO groups
Among all the patients, 834 (55.4%) were followed up for more 
than 2 years. At baseline, 27.5% of pure COPD subjects and 20.3% 
of ACO subjects experienced an acute exacerbation in the pre-
vious year (P=0.086). After 1 year, 20.9% of pure COPD subjects 
and 18.0% of ACO subjects responded that they had an acute 
exacerbation in the previous year (P=0.461). After 2 years, 19.7% 
of the pure COPD subjects and 14.3% of the ACO subjects expe-
rienced an acute exacerbation in the previous year (P=0.144). 
Pure COPD subjects showed more frequent acute exacerba-
tions than did ACO subjects; however, there was no statistically 
significant difference (Fig. 2A).
Among the 834 patients with more than 2 years of follow-up 
data, 12.7% of pure COPD subjects and 8.3% of ACO subjects 
experienced severe acute exacerbations requiring hospital ad-
mission in the previous year at baseline (P=0.150). In the re-
sults obtained after the first year, pure COPD subjects more fre-
quently had severe acute exacerbations requiring hospital ad-
mission (5.5%) in the previous year than ACO subjects (1.5%; 
P=0.030). In the results from after the second year, the same 
findings were observed (5.6% vs 0.8%; P=0.015) (Fig. 2B). Among 
pure COPD subjects with acute exacerbations, 26.5% were ad-Table 1. Comparison of demographics and clinical characteristics between 
COPD and ACO
Characteristics COPD (n=1,281) ACO (n=223) P value
Demographics
   Female 121 (9.5) 10 (4.5) 0.015
   Age 71.6±7.7 71.0±7.7 0.285
   Pack-year 44.0±25.5 45.1±24.9 0.584
   Current smoker 323 (25.3) 73 (32.9) 0.026
   BMI 22.7±3.4 23.2±3.3 0.058
Symptoms
   Cough 308 (24.3) 55 (24.9) 0.859
   Sputum 403 (32.0) 80 (36.4) 0.198
   CAT 15.9±7.9 15.1±7.8 0.172
   SGRQ 35.3±19.1 31.0±18.0 0.002
Lung function
   FEV1% 55.1±17.9 52.7±14.5 0.051
   FVC% 80.6±17.5 81.1±17.6 0.693
   FEV1/FVC 48.2±12.1 46.6±9.5 0.055
Comorbidity
   HTN 496 (39.1) 72 (32.7) 0.074
   DM 213 (16.8) 28 (12.7) 0.131
   MI 66 (5.3) 7 (3.2) 0.191
   HF 46 (3.7) 6 (2.7) 0.497
   Hyperlipidemia 135 (10.8) 16 (7.3) 0.118
   Allergic rhinitis 131 (10.4) 25 (11.4) 0.662
   Atopic dermatitis 39 (3.1) 5 (2.3) 0.518
Data are shown as mean ± standard deviation or number (%).
COPD, chronic obstructive pulmonary disease; ACO, asthma-chronic obstructive 
pulmonary disease overlap; BMI, body mass index; CAT, chronic obstructive pul-
monary disease assessment test; SGRQ, St. George Respiratory Questionnaire; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HTN, hy-
pertension; DM, diabetes mellitus; MI, myocardial infarction; HF, heart failure.
Fig. 2. Comparisons of (A) exacerbation rates, (B) severe exacerbation rates re-
quired hospitalization, and (C) prevalence of severe exacerbation, between COPD 
and ACO. COPD, chronic obstructive pulmonary disease; ACO, asthma-chronic 
obstructive pulmonary disease overlap.
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mitted to the hospital. ACO subjects were admitted less frequent-
ly (16.7%); however, there was no significant difference (P=0.051) 
(Fig. 2C).
Among all patients, 189 were followed up for more than 3 years 
and underwent pulmonary function tests at 1-year intervals. 
ACO subjects tended to recover pulmonary function over time 
(predicted FEV1: 50.2% at baseline; 58.3% after 1 year; 57.6% af-
ter 2 years; and 59.1% after 3 years). However, pulmonary func-
tion was not recovered in pure COPD subjects (predicted FEV1: 
54.1% at baseline; 55.9% after 1 year; 56.0% after 2 years; and 
53.8% after 3 years). The difference in this trend was statistically 
significant between the 2 groups (P<0.001) (Fig. 3A). Moreover, 
the changes in absolute FEV1 showed the same results as those 
for predicted FEV1 (P<0.001) (Fig. 3B).
Predictive power of the AEC for ACO
We attempted to find predictive variables for ACO. Levels of 
IgE (number of included patients, 265; odds ratio [OR], 0.999; 
P=0.177), history of asthma (number of included patients, 1,477; 
OR, 1.152; P=0.334), and history of allergic rhinitis (number of 
patients included, 1,475; OR, 1.107; P=0.662) were not signifi-
cant predictive factors. However, the AEC was a significant pre-
dictive factor for ACO (number of patients included, 1,199). We 
analyzed the predictive power of the AEC for ACO according to 
various AEC cutoff values. When we used ≥200/μL as a cutoff 
value, the OR was 1.580 (95% confidence interval, 1.150-2.17; 
P=0.005). The sensitivity and specificity were 51.4% and 59.9%, 
respectively (P=0.015). When we used a cutoff value of ≥250/
μL, the OR was significant, whereas the sensitivity and specific-
ity were not significantly predictive. The results from a cutoff 
value of ≥300/μL were not significantly predictive. Although 
the results from a cutoff value of ≥500/μL were not significant-
ly predictive, the specificity was the highest (90.3%) (Table 2).  
DISCUSSION
There are many studies showing that ACO had a poor progno-
sis compared with pure COPD. However, this cohort study de-
termined that ACO is a distinct phenotype of COPD represent-
ing better clinical outcomes. First, we observed that patients 
with ACO had the possibility of recovering their lung function. 
In fact, the baseline lung function at the first visit was poorer in 
patients with ACO than that in those with COPD in this cohort 
study. However, the decline in lung function was more remark-
able in patients with pure COPD than those with ACO in this 
cohort study. Some cross-sectional studies reported that patients 
with ACO demonstrated poorer lung function than those with 
pure COPD.17 However, Kauppi et al.18 reported that the post-
BD FEV1 was significantly better in ACO (67.4%) than in pure 
COPD (61.4%). In addition, De Marco et al.11 showed a rapid 
decline in FEV1 in pure COPD (-7.64 mL/year) in contrast to an 
improvement in FEV1 in ACO (1.62 mL/year), which is consis-
tent with our result. The recovery of lung function in ACO might 
be due to an asthma component with a good response to ICS 
treatment. Thus, we suggest that the possibility of recovering 
lung function may be the same characteristics of ACO com-
pared as pure COPD.
Second, we revealed that the severe exacerbation rate was low-
er in ACO compared with pure COPD. Some studies reported 
Table 2. Predictive power of AEC for ACO
Cut-off value OR (95% CI) P value Sensitivity (%)
Specificity 
(%) P value
AEC ≥200 1.580 (1.150-2.170) 0.005 51.4 59.9 0.015
AEC ≥250 1.448 (1.046-2.004) 0.026 49.6 41.1 0.068
AEC ≥300 1.313 (0.925-1.866) 0.128 29.3 76.0 0.254
AEC ≥500 1.284 (0.786-2.100) 0.318 12.2 90.3 0.602
AEC, absolute eosinophil count; ACO, asthma-chronic obstructive pulmonary 
disease overlap; OR, odds ratio; CI, confidence interval.
Fig. 3. Comparison of pulmonary function trends between COPD and ACO. Predicted FEV1 (A) and absolute FEV1 (B) are shown. COPD, chronic obstructive pulmonary 
disease; ACO, asthma-chronic obstructive pulmonary disease overlap; FEV1, forced expiratory volume in 1 second.
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that the exacerbation rate was higher in ACO than in COPD.5,10 
This cohort study showed similar total exacerbation rates be-
tween ACO and pure COPD. However, we showed that severe 
exacerbation requiring hospital admission was more frequent 
among patients with pure COPD. This result may be associated 
with the results of the previous studies which described that pa-
tients with COPD had a lower chance of recovering lung func-
tion. Izquierdo-Alonso et al.19 previously showed that the exac-
erbation rate was lower in ACO (64.9%) compared with COPD 
of the emphysema type (68.8%). In addition, they showed that 
the number of visits to the emergency department was slightly 
lower in ACO (0.79/year) compared with COPD of the emphy-
sema type (1.12/year) and COPD of the bronchitis type (1.25/
year); however, the difference was not statistically significant. 
The higher survival rate among ACO patients was confirmed by 
Cosio et al.12 and this may be understood in the same context as 
in this cohort study. Further studies are needed to differentiate 
severe exacerbation rates between ACO and COPD.
Finally we showed that the symptoms were better in ACO com-
pared pure COPD. Many studies reported that symptoms and 
quality of life were worse in ACO compared with pure COPD.8,18,20,21 
Some studies showed that symptoms and quality of life in ACO 
were not different from those in COPD.5 It was difficult to find 
studies showing better symptoms in ACO, in concordance with 
this cohort study. Although data are not shown, SGRQ-C was 
significantly correlated with exacerbation rate and lung function 
recovery. Multivariate analysis showed that ACO was a depen-
dent prognostic factor on SGRQ-C for exacerbation and lung 
function recovery. Then, we can suggest that subjects with ACO 
have less severe symptoms, and therefore it might lead to rare 
severe exacerbation, and the possibility of lung function recovery.
The result that ACO showed better clinical outcomes than pure 
COPD in this cohort study is in contrast to major opinions sup-
ported by extensive studies. The main reason is due to the dif-
ferences in study design. This cohort study included treatment-
naïve and ICS-naïve subjects. Moreover, the mean treatment 
duration was relatively short (4-5 years) compared with those 
in other studies (usually more than 10 years). These might have 
caused ACO to show better clinical outcomes after enrollment 
in the cohort study followed by proper ACO management. An-
other reason is due to the unique asthma characteristics in Ko-
rea. Asthma is diagnosed and managed mainly in primary care. 
In Korea, the prevalence of asthma is estimated to be about 3%-
5%, whereas it is thought to be 8%-20% in other countries. Many 
Korean asthmatic patients do not use ICS treatment properly 
(the treatment rate is lower than 50%), especially in primary 
care.22 Moreover, the asthma fatality rate per 100,000 asthmatics 
is 7%-9% in Korea, whereas it is less than 5% in most countries. 
This means that many primary clinics missed the diagnosis of 
asthma, and even physician-diagnosed asthma patients do not 
use their treatment drug properly. These unique asthma char-
acteristics in Korea might have induced the ACO subjects to have 
a lesser opportunity to treat their asthma properly prior to en-
rollment, and finally, their prognoses improved after enrollment 
in the cohort study which consisted of pateints from second or 
tertiary hospitals following proper ACO management, includ-
ing ICS treatment.
ACOS has recently received attention, and the definition of 
ACOS has not been established. The Spanish criteria,23 modi-
fied Spanish criteria,12 and European Respiratory Journal (ERJ) 
criteria24 are the most prominent criteria, and require that vari-
ous items be fulfilled to diagnose ACOS. The Spanish criteria 
were created in 2012 and include eosinophilia in sputum, a his-
tory of atopy, and the level of total IgE. However, in practice, many 
institutes cannot assess eosinophilia in sputum. The modified 
Spanish criteria and ERJ criteria were created in 2016 and ex-
clude sputum eosinophilia, and instead include blood eosino-
philia. However, these criteria still contain 6 items. Many stud-
ies have attempted to diagnose ACOS simply and properly;25 how-
ever, there is still no consensus. Caillaud et al.5 defined ACOS 
very simply as follows: a patient enrolled in a COPD cohort study 
who was diagnosed with asthma by a physician before the age 
of 40 years. We used very simplified criteria for ACO: the inter-
section of asthma and COPD, as defined by the 2014 GINA and 
GOLD guidelines, with a BDR (post-BD FEV1 improvements of 
12% and 200 mL).
Some researchers believe that a BDR is not credible to identify 
the phenotype of COPD, ACO.26 However, there are many stud-
ies that used simplified criteria for ACOS as this study did (in 
the assumptions on COPD). Fu et al.6 (BDR or airway hyper-re-
sponsiveness), Menezes et al.17 (BDR and wheezing), Kauppi et 
al.18 (BDR including PEF and an exercise test), and Contoli et 
al.27 (BDR and a history of asthma) used relatively simple crite-
ria, including BDR and/or other simple conditions. Recently, 
Baarnes et al.28 showed similar characteristics in ACOS defined 
by wheezing, BDR, or both, and they concluded that ACOS could 
be identified only by BDR as in this cohort study. In addition, 
considering the prevalence of ACOS among COPD, which is 
15%-25% as defined by various criteria,5,29-31 the prevalence of 
ACOS in this study (14.8%) indicates that the definition used in 
this study does not differ substantially from the more compli-
cated classic criteria previously described. Thus, we thought 
that the simplified criteria for ACOS used in this study could be 
applied. However, some researchers still have questions wheth-
er COPD with mild BDR is sufficient to define ACOS. Barnes9 
described that ACO is better to include the various phenotypes 
of status with features of COPD and asthma: COPD with mild 
BDR, COPD with eosinophilic inflammation, asthma with smok-
ing history, and asthma with neutrophilic inflammation. Further-
more,the 2017 GINA guideline also used the term of ACO.13 Then, 
we used the term of ACO described by Barnes and the 2017 GI-
NA guideline rather than ACOS to avoid controversy.
When we attempted to find predictive variables for ACO, 
blood eosinophil count was significantly superior to the level of 
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total IgE, history of asthma, and history of allergic rhinitis. More-
over, the most powerful cutoff value for eosinophil count was 
200/μL. The modified Spanish criteria and ERJ criteria contain 
a history of asthma as a major criterion, whereas they include 
blood eosinophil count as a minor criterion; the cutoff values 
for blood eosinophilia were 5% and 300/μL in the modified Spa-
nish criteria and ERJ criteria, respectively. We suggest that the 
blood eosinophil count will be a better predictive marker for 
ACO than expected. Additionally, the adjusted cutoff value for 
blood eosinophilia can be applied to stronger predictive power 
in ACO.
This study has several limitations. First, ACO as defined in this 
study might not be the correct definition of ACO. Additionally, 
we could not apply the definition previously described (GINA 
and GOLD guidelines, Spanish criteria, modified Spanish crite-
ria, and ERJ criteria), as this cohort study did not contain all the 
parameters described in those criteria. Second, only 50% and 
13% of subjects were followed up for 2 years and 3 years, respec-
tively, and they were analyzed for exacerbation and lung func-
tion. Almost all excluded patients in the follow-up study were 
recently enrolled patients in the cohort study. However, we can-
not exclude a selection bias in which subjects who were more 
compliant might have been enrolled in larger numbers in the 
follow-up study. Third, there were some missing values for the 
level of total IgE, blood eosinophil count, history of asthma, and 
history of allergic rhinitis. Moreover, a history of asthma should 
be changed to a history of asthma before the age of 40 years for 
better evaluation. Finally we cannot fully exclude the possibility 
of selection bias. The results that ACO patients showed less symp-
toms might be brought about by selection bias. KOCOSS cohort 
data were collected from 45 institutions across the country for 5 
years. The recruitment and enrollment of subjects are still on-
going, and it is necessary to review the results of the re-analysis 
of the long-term follow-up data.
This COPD cohort study defined ACO (14.8%), which is a dis-
tinct type of COPD. We suggest that subjects with ACO have less 
severe symptoms, and therefore it might lead to rare severe ex-
acerbation and the possibility of lung function recovery. More-
over, blood eosinophil count (≥200/μL) could be a suitable pre-
dictive factor for ACO.
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